NCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
7 trialsNCT03228537 2025-11-10
Atezolizumab, Pemetrexed Disodium, Cisplatin, and Surgery With or Without Radiation Therapy in Treating Patients With Stage I-III Pleural Malignant Mesothelioma
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT04996017 2025-03-13
AtezoMeso
Gruppo Oncologico Italiano di Ricerca Clinica
Phase 3 Recruiting
NCT04480372 2024-07-01
SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II
Swiss Cancer Institute
Phase 2 Completed
NCT03654833 2023-03-14
MiST
University of Leicester
Phase 2 Unknown
NCT05429866 2023-03-08
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Jules Bordet Institute
Phase 2 Unknown
NCT03786419 2021-05-13
A Study of Atezolizumab in Unresectable or Advaced Malignant Pleural Mesothelioma
Health Pharma Professional Research
Phase 2 Withdrawn